ciltacabtagene autoleucel

all catalysts(0)

nothing on the calendar yet

News(10)

• Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
  Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.
  biopharma_dive · 16h ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 7d ago
• Chutes & Ladders—Legend CEO departs without successor in place
  Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
  fiercebiotech · 12d ago
• J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
  The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
  biopharma_dive · 12d ago
• J&J secures right to take the helm in up to $925M Sail CAR T pact
  As part of the collaboration, Johnson & Johnson will have an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion.
  biospace · 12d ago
• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 15d ago
• Legend CEO Ying Huang resigns; Carvykti chief named interim leader
  Legend Biotech, the developer of the blockbuster cancer therapy Carvykti, is in the market for a new CEO. Ying Huang stepped down Friday after serving as CEO since November 2020, Legend announced in a
  endpoints · 15d ago
• Legend Biotech CEO abruptly steps down without permanent replacement
  In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
  fiercebiotech · 15d ago
• Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
  Safety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this sp…
  biospace · 16d ago
• Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
  Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
  biospace · 20d ago